ECSP089000A - Cristal novedoso de ácido propiónico de 3-[5-(4-(ciclopentiloxi)-2-hidroxibenzoílo]-2-[(3-hidroxi-1,2-benzisozazol-6-ilo)metoxi]-fenilo] - Google Patents

Cristal novedoso de ácido propiónico de 3-[5-(4-(ciclopentiloxi)-2-hidroxibenzoílo]-2-[(3-hidroxi-1,2-benzisozazol-6-ilo)metoxi]-fenilo]

Info

Publication number
ECSP089000A
ECSP089000A EC2008009000A ECSP089000A ECSP089000A EC SP089000 A ECSP089000 A EC SP089000A EC 2008009000 A EC2008009000 A EC 2008009000A EC SP089000 A ECSP089000 A EC SP089000A EC SP089000 A ECSP089000 A EC SP089000A
Authority
EC
Ecuador
Prior art keywords
crystal
ilo
propionic acid
hydroxibenzoil
ciclopentiloxi
Prior art date
Application number
EC2008009000A
Other languages
English (en)
Inventor
Kenji Yonezawa
Hironori Kotsubo
Yasutaka Baba
Yukie Tada
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of ECSP089000A publication Critical patent/ECSP089000A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

El cristal de ácido propiónico de 3-(5-[4-(ciclopentiloxi)-2-hidroxibenzoilo]-2-[(3-hidroxi-1,2-benzisoxazol-6-ilo)metoxi]fenilo) tiene picos en las posiciones de 14.0, 16.0, 23.3, 23.7 y 26.3° y el cristal de ácido propiónico de 3-(5-[4-(ciclopentiloxi)-2-hidroxibenzoilo]-2-[(3-hidroxi-1,2-benzisoxazol-6-ilo)metoxi]fenilo) que tiene picos en la posición de 4.6, 23.1, 24.7, 25.6 y 26.0° en 2 del ángulo de difracción en un patrón de difracción de rayos X de polvo con un pequeño volumen específico, son difíciles de cargar con electricidad, son fáciles de manejar y útiles como un ingrediente farmacéutico activo de agentes antirreumáticos excelentes.
EC2008009000A 2006-05-26 2008-12-23 Cristal novedoso de ácido propiónico de 3-[5-(4-(ciclopentiloxi)-2-hidroxibenzoílo]-2-[(3-hidroxi-1,2-benzisozazol-6-ilo)metoxi]-fenilo] ECSP089000A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006146220 2006-05-26

Publications (1)

Publication Number Publication Date
ECSP089000A true ECSP089000A (es) 2009-02-27

Family

ID=38778516

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008009000A ECSP089000A (es) 2006-05-26 2008-12-23 Cristal novedoso de ácido propiónico de 3-[5-(4-(ciclopentiloxi)-2-hidroxibenzoílo]-2-[(3-hidroxi-1,2-benzisozazol-6-ilo)metoxi]-fenilo]

Country Status (27)

Country Link
US (1) US7977492B2 (es)
EP (1) EP2022788B1 (es)
JP (1) JP5117381B2 (es)
KR (1) KR101389038B1 (es)
CN (1) CN101454298B (es)
AT (1) ATE479666T1 (es)
AU (1) AU2007268771B2 (es)
BR (1) BRPI0712909A2 (es)
CA (1) CA2652939C (es)
CY (1) CY1111398T1 (es)
DE (1) DE602007008882D1 (es)
DK (1) DK2022788T3 (es)
EC (1) ECSP089000A (es)
ES (1) ES2351065T3 (es)
HR (1) HRP20100544T1 (es)
IL (1) IL195416A (es)
MA (1) MA30510B1 (es)
MX (1) MX2008014906A (es)
NO (1) NO20084632L (es)
NZ (1) NZ573034A (es)
PL (1) PL2022788T3 (es)
PT (1) PT2022788E (es)
RS (1) RS51517B (es)
RU (1) RU2429233C2 (es)
SI (1) SI2022788T1 (es)
WO (1) WO2007138996A1 (es)
ZA (1) ZA200809922B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ593062A (en) * 2006-02-21 2012-04-27 Toyama Chemical Co Ltd Process for production of 3-[5-[4-cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process
DK2258361T3 (da) * 2008-03-27 2014-10-27 Toyama Chemical Co Ltd ANVENDELSE AF ET BENZOPHENONDERIVAT ELLER ET SALT DERAF I KOMBINATION MED EN TNFalfa-INHIBITOR OG FARMACEUTISK SAMMENSÆTNING INDEHOLDENDE DERIVATET ELLER SALTET DERAF OG INHIBITOREN
WO2009131098A1 (ja) 2008-04-22 2009-10-29 富山化学工業株式会社 ベンゾフェノン誘導体またはその塩および免疫抑制剤を組み合わせて使用する方法ならびにこれらを含有する医薬組成物
CN103183647B (zh) * 2011-12-28 2017-06-09 天津市国际生物医药联合研究院有限公司 3‑{[2‑[3‑氧‑(1,2‑苯并异噻唑‑6‑基)甲氧基‑5‑(2‑羟基‑4‑环戊氧基苯甲酰基)]苯基}丙酸的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042150A (en) 1960-01-26 1962-07-03 Lukawsky Michael Emergency brake and anti-skid device
AU7083894A (en) * 1993-07-06 1995-02-06 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of benzodiazepine derivative
EP1127869A4 (en) 1998-11-05 2007-05-02 Toyama Chemical Co Ltd NOVEL COMPOUNDS AND THEIR MEDICAL USE
JP4976617B2 (ja) 2000-03-17 2012-07-18 富山化学工業株式会社 新規なベンゾフェノン誘導体およびその塩
BR0214177A (pt) 2001-11-16 2004-09-14 Toyama Chemical Co Ltd Derivado de benzofenona, agente preventivo ou terapêutico para uma doença em que está envolvida expressão excessiva de ap-1, e, inibidor de ap-1

Also Published As

Publication number Publication date
KR20090014194A (ko) 2009-02-06
NO20084632L (no) 2008-12-12
HRP20100544T1 (hr) 2010-11-30
CN101454298A (zh) 2009-06-10
WO2007138996A1 (ja) 2007-12-06
EP2022788B1 (en) 2010-09-01
ZA200809922B (en) 2010-02-24
ATE479666T1 (de) 2010-09-15
SI2022788T1 (sl) 2011-01-31
CA2652939A1 (en) 2007-12-06
JP5117381B2 (ja) 2013-01-16
PL2022788T3 (pl) 2011-03-31
RS51517B (en) 2011-06-30
MX2008014906A (es) 2008-12-09
MA30510B1 (fr) 2009-06-01
JPWO2007138996A1 (ja) 2009-10-08
RU2008151778A (ru) 2010-07-10
EP2022788A1 (en) 2009-02-11
US7977492B2 (en) 2011-07-12
RU2429233C2 (ru) 2011-09-20
CN101454298B (zh) 2011-11-16
AU2007268771B2 (en) 2011-12-01
EP2022788A4 (en) 2009-06-24
PT2022788E (pt) 2010-10-04
IL195416A (en) 2012-07-31
CA2652939C (en) 2014-12-02
CY1111398T1 (el) 2015-08-05
DK2022788T3 (da) 2010-12-13
KR101389038B1 (ko) 2014-04-28
NZ573034A (en) 2010-08-27
US20090275757A1 (en) 2009-11-05
BRPI0712909A2 (pt) 2012-10-02
AU2007268771A1 (en) 2007-12-06
IL195416A0 (en) 2009-08-03
ES2351065T3 (es) 2011-01-31
DE602007008882D1 (de) 2010-10-14

Similar Documents

Publication Publication Date Title
FR21C1025I1 (fr) Composition parasiticide comprenant un agent actif d'isoxazoline, son procede et utilisation
AR075523A1 (es) 4-metilbencenosulfonato de 6-metil-5-(1-metil-1h-pirazol-5-il)-n-[[5-(metilsulfonil)piridin-2-il]metil]-2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida y modificacion cristalina del mismo, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de enfer
IL223002A0 (en) Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
NZ591619A (en) Nitrogen-containing heterocyclic compound and pest control agent
PL2947072T3 (pl) 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
CR11038A (es) Derivados de aril isoxazolina insecticidas
BRPI0702340A (pt) dispositivo de entrega de fármaco
AR054278A1 (es) Formas polimorficas del ester etilico del acido 3-((2-{ (4-(hexiloxicarbonilamino- imino-metil)- fenilamino)-metil} -1-metil-h-bencimidazol-5- carbonil) piridin-2-il-amino)-propionico
ECSP089000A (es) Cristal novedoso de ácido propiónico de 3-[5-(4-(ciclopentiloxi)-2-hidroxibenzoílo]-2-[(3-hidroxi-1,2-benzisozazol-6-ilo)metoxi]-fenilo]
UY29835A1 (es) Formas de dosificación farmacéutica sólidas que comprenden 5-cloro-n-(((5s)-2-oxo-3-(4-(3-oxo-4-morfolinil)fenil)-1,3-oxazolidin-5-il)metil)-2-tiofenocarboxamida
IL206470A (en) 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It
CY1111701T1 (el) Υδροχλωρικο αλας του 5-[3-(3-υδροξυφαινοξυ)αζετιδιν-1-υλ]-5-μεθυλ-2,2-διφαινυλεξαναμιδιου
DK3252069T3 (da) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-oner til behandling af sygdomme
CR9432A (es) Derivado de bencimidazol y uso como antagonista de angiotensina ii
UY31151A1 (es) Inhalador
CR20150001A (es) Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil) fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
UY34295A (es) Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
UA111324C2 (uk) Агент для профілактики або зменшення пігментації
ATE468333T1 (de) N-cyanoalkylanthranilamide als insektizide
DK2022497T3 (da) Oral sammensætning, omfattende 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxyphenylpropionsyre eller salt deraf
DK2300452T3 (da) 5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister
AR065597A1 (es) Compuesto ester y su uso
WO2009075250A1 (ja) 植物病害防除剤
AR059107A1 (es) Compuesto ester y su utilizacion
UY34194A (es) ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?